Focus of New NOSI—Complement Components in Immune Responses

The recently published Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI) seeks investigators who can contribute to accelerating our understanding of the roles that complement components (molecules and receptors) have in immune responses against infectious agents.

Specifically, 1) roles that complement components and/or receptors have in the initiation, magnitude, maintenance, and quality of immune responses against infectious agents or 2) roles that complement components play in developing immune-mediated pathogenic responses following infection.

The results of CIBI-supported studies will inform the development of adjuvants and vaccine candidates or therapeutics that target complement components.

Research areas of interest include the following:

• Studies of the role of complement during adaptive or innate immune cell activation, differentiation, function, homeostasis, and memory
• Mechanisms regulating the crosstalk of complement with other innate receptor systems
• The potential of targeting complement components in adjuvant development
• The role of complement components in immune pathogenesis of infection
• Development of animal models or cell- or tissue-specific in vitro and in vivo systems for studying the roles of complement in regulating immune responses

Application and Submission Details

Note that this NOSI applies to due dates on or after June 5, 2021, and subsequent receipt dates through January 7, 2023.

Submit applications using one of the following funding opportunity announcements or any reissues of these announcements through January 8, 2023, the expiration date of this notice:

• NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed)
• NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed)

Be sure to follow all instructions in the SF 424 (R&R) Application Guide and include “NOT-AI-21-008” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF 424 R&R form; otherwise, your application will not be considered for this initiative.

Have Questions?

Direct them to Dr. Cheryl Lapham, the NOSI’s scientific/research contact.